Objective: Atomoxetine’s tolerance and efficacy were studied in 24 patients with pervasive developmental disorder and symptoms of ADHD. Method: Prospective, open-label, 16-week study was performed, using the variables of the Clinical Global Impression Scale and the Conners’ Scale, among others. Results: A significant difference was found between pre- and posttreatment scores as well as a significant reduction was found on the scales used. Only five patients presented adverse events. Conclusion: Atomoxetine therefore appears to be a useful drug, pointing to the need for larger, randomized, controlled, double-blind studies to confirm its efficacy versus placebo and in comparison with other treatment options.
AmanM. G.FarmerC. A.HollwayJ.ArnoldL. E. (2008). Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America, 17, 713-738,.vii. doi:S1056-4993(08)00039-4 [pii]10.1016/j.chc.2008.06.009
2.
AmanM. G.LamK. S.Van BourgondienM. E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15, 116-126. doi:10.1089/cap.2005.15.116
3.
AmanM. G.SinghN. N.StewartA. W.FieldC. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.
4.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
5.
ArnoldL. E.AmanM. G.CookA. M.WitwerA. N.HallK. L.ThompsonS.RamadanY. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1196-1205. doi: 10.1097/01.chi.0000231976.28719.2aS0890-8567(09)62374-1 [pii]
6.
BirmaherB.QuintanaH.GreenhillL. L. (1988). Methylphenidate treatment of hyperactive autistic children. Journal of the American Academy of Child & Adolescent Psychiatry, 27, 248-251.
7.
BreretonA. V.TongeB. J.EinfeldS. L. (2006). Psychopathology in children and adolescents with autism compared to young people with intellectual disability. Journal of Autism and Developmental Disorders, 36, 863-870. doi: 10.1007/s10803-006-0125-y
8.
CharnsilC. (2010). Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study. Journal of Attention Disorders, 4, [Epub ahead of print] doi: 1087054710376907 [pii]10.1177/1087054710376907
9.
ConnersC. K. (Ed.). (1997). Conners’ Rating Scales–Revised: Technical Manual. Toronto, Ontario, Canada: Multi-Health Systems Inc.
10.
ConnersC. K. (Ed.). (2000). Conner’s continuous performance test-II. North Tonawanda, NY:Multi-Health Systems Inc.
11.
Di MartinoA.MelisG.CianchettiC.ZuddasA. (2004). Methylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. Journal of Child and Adolescent Psychopharmacology, 14, 207-218. doi: 10.1089/1044546041649011
12.
DuPaulG.PowerT. J.AnastopoulosA. D.ReidR. (Eds.). (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York, NY: Guilford.
13.
FarreA.NarbonaJ. (Eds.). (1998). EDAH. Escalas para la evaluación del trastorno por déficit de atención/hiperactividad [EDAH. Scales for attention deficit/hiperactivity disorder evaluation]. Madrid, Spain: TEA.
14.
GadowK. D.DevincentC. J.PomeroyJ.AzizianA. (2005). Comparison of DSM-IV symptoms in elementary school-age children with PDD versus clinic and community samples. Autism, 9, 392-415. doi: 9/4/392 [pii]10.1177/1362361305056079
15.
GellerD.DonnellyC.LopezF.RubinR.NewcornJ.SuttonV.. . . SumnerC. (2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 1119-1127. doi: 10.1097/chi.0b013e3180ca8385S0890-8567(09)61930-4 [pii]
16.
GoyetteC. H.ConnersC. K.UlrichR. F. (1978). Normative data on revised Conners Parent and Teacher Rating Scales. Journal of Abnormal Child Psychology, 6, 221-236.
17.
GuyW. (Ed.). (1976). ECDEU Assessment Manual of Psychopharmacology (NIMH Publication 76–338). Washington, DC: Department of Health, Education, and Welfare, National Institute of Mental Health.
18.
HandenB. L.JohnsonC. R.LubetskyM. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255.
19.
HazellP. (2007). Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. Journal of Paediatrics and Child Health, 43, 19-24. doi: JPC995 [pii]10.1111/j.1440-1754.2007.00995.x
20.
JouR. J.HandenB. L.HardanA. Y. (2005). Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15, 325-330. doi: 10.1089/cap.2005.15.325
21.
McCarthyJ. (2007). Children with autism spectrum disorders and intellectual disability. Current Opinion in Psychiatry, 20, 472-476. doi: 10.1097/YCO.0b013e32821f609500001504-200709000-00009 [pii]
22.
MichelsonD.AllenA. J.BusnerJ.CasatC.DunnD.KratochvilC.. . . HarderD. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
23.
MichelsonD.FariesD.WernickeJ.KelseyD.KendrickK.SalleeF. R.SpencerT. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics,108, E83. doi: 108/5/e83 [pii]
24.
Montanes-RadaF.Gangoso-FermosoA. B.Martiinez-GraneroM. A. (2009). Drugs for attention deficit hyperactivity disorder. Revista de Neurología, 48, 469-481. doi: rn2008239 [pii]
25.
MyersS. M. (2007). The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy, 8, 1579-1603. doi: 10.1517/14656566.8.11.1579
26.
Network Research Units on Pediatric Psychopharmacology Autism. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266-1274. doi: 62/11/1266 [pii]10.1001/archpsyc.62.11.1266
27.
PoseyD. J.AmanM. G.McCrackenJ. T.ScahillL.TierneyE.ArnoldL. E.. . . McDougleC. J. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61, 538-544. doi: S0006-3223(06)01215-7[pii]10.1016/j.biopsych.2006.09.028
28.
PoseyD. J.WiegandR. E.WilkersonJ.MaynardM.StiglerK. A.McDougleC. J. (2006). Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16, 599-610. doi: 10.1089/cap.2006.16.599
29.
PrasadS.SteerC. (2008). Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: Clinical approaches and review of current available evidence. Paediatric Drugs, 10, 39-47. doi: 1015 [pii]
30.
QuintanaH.BirmaherB.StedgeD.LennonS.FreedJ.BridgeJ.GreenhillL. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283-294.
31.
SantoshP. J.BairdG.PityaratstianN.TavareE.GringrasP. (2006). Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child: Care, Health and Development, 32, 575-583. doi: CCH631 [pii] 10.1111/j.1365-2214.2006.00631.x
32.
SchoplerE.ReichlerR. J.DeVellisR. F.DalyK. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10, 91-103.
33.
ServeraM.CardoE. (2007). ADHD Rating Scale-IV in a sample of Spanish schoolchildren: Normative data and internal consistency for teachers and parents. Revista de Neurología, 45, 393-399. doi: rn2007301 [pii]
34.
SwansonJ. (Ed.). (1992). School-based assessments and interventions for ADD students. Irvine, CA: KD Publishing.
35.
TroostP. W.SteenhuisM. P.Tuynman-QuaH. G.KalverdijkL. J.BuitelaarJ. K.MinderaaR. B.HoekstraP. J. (2006). Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. Journal of Child and Adolescent Psychopharmacology, 16, 611-619. doi: 10.1089/cap.2006.16.611
36.
TseW. S.BondA. J. (2002). Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl),159, 216-221. doi: 10.1007/s00213-001-0926-9
37.
Van BruntD. L.JohnstonJ. A.YeW.PohlG. M.SunP. J.SterlingK. L.DavisM. E. (2005). Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder. Pharmacotherapy, 25, 1541-1549. doi: 10.1592/phco.2005.25.11.1541
38.
VaughanB.FegertJ.KratochvilC. J. (2009). Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacotherapy, 10, 669-676. doi: 10.1517/14656560902762873
